Dupont Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Dupont Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-33,192	Closed	-$6.1M	–	2042
2021 Q2	$6.1M	Buy	33,192 +4,330	+15%	+$743K	0.14%	111
2021 Q1	$4.41M	Buy	28,862 +7,177	+33%	+$1.11M	0.11%	148
2020 Q4	$3.39M	Buy	21,685 +9,912	+84%	+$1.27M	0.07%	221
2020 Q3	$1.35M	Sell	11,773 -6,344	-35%	-$684K	0.03%	405
2020 Q2	$2.03M	Sell	18,117 -1,736	-9%	-$184K	0.04%	307
2020 Q1	$1.78M	Sell	19,853 -5,130	-21%	-$503K	0.04%	319
2019 Q4	$2.7M	Buy	24,983 +10,813	+76%	+$1.16M	0.06%	281
2019 Q3	$1.39M	Sell	14,170 -1,274	-8%	-$144K	0.03%	433
2019 Q2	$2.02M	Buy	15,444 +1,489	+11%	+$192K	0.05%	369
2019 Q1	$1.89M	Sell	13,955 -3,463	-20%	-$431K	0.04%	385
2018 Q4	$1.7M	Buy	+17,418	New	+$2.06M	0.04%	392
2018 Q2	–	Sell	-1,973	Closed	-$220K	–	1057
2018 Q1	$220K	Buy	+1,973	New	+$236K	0.01%	803
2017 Q4	–	Sell	-1,111	Closed	-$156K	–	1016
2017 Q3	$156K	Buy	+1,111	New	+$151K	﹤0.01%	826
2015 Q3	–	Sell	-1,150	Closed	-$208K	–	646
2015 Q2	$208K	Buy	+1,150	New	+$198K	﹤0.01%	549
2014 Q4	–	Sell	-11,900	Closed	-$1.97M	–	661
2014 Q3	$1.97M	Sell	11,900 -16,959	-59%	-$2.79M	0.03%	331
2014 Q2	$4.51M	Buy	28,859 +5,832	+25%	+$921K	0.07%	217
2014 Q1	$3.5M	Buy	+23,027	New	+$3.66M	0.06%	262

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Dupont Capital Management's ALXN Position: Q3 2021 in Review

Dupont Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 33,192 shares — an estimated $6.1M sold.

Dupont Capital Management first reported a position in ALXN in Q1 2014 and held it in 17 quarters. The position peaked at $6.1M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Dupont Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Dupont Capital Management sold 33,192 Alexion Pharmaceuticals shares in Q3 2021, an estimated $6.1M.
Dupont Capital Management first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 17 quarters.
Dupont Capital Management's Alexion Pharmaceuticals position peaked at $6.1M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Dupont Capital Management's 13F filing for Q3 2021, filed 3 Nov 2021.